FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311744554> ?p ?o ?g. }

• W4311744554 abstract "Abstract Background Ensitrelvir is a new drug candidate to treat COVID-19 disease. According to the in vitro drug-drug interaction (DDI) study, time-dependent inhibition by ensitrelvir was observed on cytochrome P450 3A (CYP3A). The purpose of this study was to evaluate the effect of ensitrelvir on the pharmacokinetics (PK) of CYP3A substrates by clinial DDI studies and physiologically-based pharmacokinetic (PBPK) analyses. Methods Clinical studies: The effect of once daily multiple-doses of ensitrelvir with the loading dose on Day 1/ maintenance dose (750/250 mg) for 6 days on the PK of midazolam (MDZ) was assessed. MDZ was administered on Days -2 and 6. The effects of once daily multiple-doses of ensitrelvir with 750/250 mg for 5 days on the PK of dexamethasone (DXS) and prednisolone (PLS) were also assessed because these corticosteroids were also CYP3A substrates. DXS and PLS were administered on Days -2, 5 (co-administration with ensitrelvir), 9 and 14 to evaluate the effects after the last dose of ensitrelvir. PBPK analyses: The effects of once daily multiple-doses of ensitrelvir with another dose regimen (the loading dose/mentenance dose [375/125 mg] for 5 days) on the PK of CYP3A substrates were predicted using Simcyp PBPK Simulator (Version 20, Certara UK Limited, UK). Results The AUC0-inf of MDZ co-administered with ensitrelvir was increased by 8.80-fold compared to those of MDZ alone, indicating that ensitrelvir is a strong CYP3A inhibitor with 750/250 mg for 6 days. The AUC0-inf of DXS on Day 5 was increased 3.47-fold and the effect of ensitrelvir on the PK of DXS was diminished over time after the last dose of ensitrelvir. The AUC0-inf of PLS on Day 5 was increased 1.25-fold and no clinically meaningful effect of ensitrelvir on the PK of PLS was observed. The PBPK analyses predicted that the co-administration of ensitrelvir increased the AUC of MDZ by 3.83-fold and the AUC of DXS by 2.49-fold following ensitrelvir at 375/125 mg for 5 days. A clinical study with MDZ under the analyses conditions is underway to confirm the PBPK results. Conclusion The clinical study revealed that ensitrelvir affects the PK of CYP3A substrates with 750/250 mg for 5 or 6 days. The PBPK analyses suggests that ensitrelvir is expected to a moderate inhibitor of CYP3A with 375/125 mg for 5 days. Disclosures Ryosuke Shimizu, Shionogi & Co., Ltd.: employee Kana Horiuchi, Shionogi & Co., Ltd.: employee Hiroki Koshimichi, n/a, Shionogi & Co., Ltd.: employee Takanobu Matsuzaki, Ph.D., Shionogi & Co., Ltd.: Employee Shinpei Yoshida, Ph.D., Shionogi & Co., Ltd.: employee Shingo Sakamoto, n/a, Shionogi & Co., Ltd.: employee Ryuji Kubota, Ph.D., Shionogi & Co., Ltd.: employee|Shionogi & Co., Ltd.: employee." @default.
• W4311744554 created "2022-12-28" @default.
• W4311744554 creator A5043666689 @default.
• W4311744554 creator A5070169034 @default.
• W4311744554 creator A5070775092 @default.
• W4311744554 creator A5071976641 @default.
• W4311744554 creator A5074367560 @default.
• W4311744554 creator A5080055144 @default.
• W4311744554 creator A5089714910 @default.
• W4311744554 date "2022-12-01" @default.
• W4311744554 modified "2023-09-23" @default.
• W4311744554 title "1131. Evaluation of drug-drug interaction potential of ensitrelvir for CYP3A by clinical studies and physiologically-based pharmacokinetic model" @default.
• W4311744554 doi "https://doi.org/10.1093/ofid/ofac492.970" @default.
• W4311744554 hasPublicationYear "2022" @default.
• W4311744554 type Work @default.
• W4311744554 citedByCount "0" @default.
• W4311744554 crossrefType "journal-article" @default.
• W4311744554 hasAuthorship W4311744554A5043666689 @default.
• W4311744554 hasAuthorship W4311744554A5070169034 @default.
• W4311744554 hasAuthorship W4311744554A5070775092 @default.
• W4311744554 hasAuthorship W4311744554A5071976641 @default.
• W4311744554 hasAuthorship W4311744554A5074367560 @default.
• W4311744554 hasAuthorship W4311744554A5080055144 @default.
• W4311744554 hasAuthorship W4311744554A5089714910 @default.
• W4311744554 hasConcept C112705442 @default.
• W4311744554 hasConcept C11824378 @default.
• W4311744554 hasConcept C126322002 @default.
• W4311744554 hasConcept C185867374 @default.
• W4311744554 hasConcept C2776814716 @default.
• W4311744554 hasConcept C2778000748 @default.
• W4311744554 hasConcept C2780035454 @default.
• W4311744554 hasConcept C2781413609 @default.
• W4311744554 hasConcept C526171541 @default.
• W4311744554 hasConcept C62231903 @default.
• W4311744554 hasConcept C71924100 @default.
• W4311744554 hasConcept C97320921 @default.
• W4311744554 hasConcept C98274493 @default.
• W4311744554 hasConceptScore W4311744554C112705442 @default.
• W4311744554 hasConceptScore W4311744554C11824378 @default.
• W4311744554 hasConceptScore W4311744554C126322002 @default.
• W4311744554 hasConceptScore W4311744554C185867374 @default.
• W4311744554 hasConceptScore W4311744554C2776814716 @default.
• W4311744554 hasConceptScore W4311744554C2778000748 @default.
• W4311744554 hasConceptScore W4311744554C2780035454 @default.
• W4311744554 hasConceptScore W4311744554C2781413609 @default.
• W4311744554 hasConceptScore W4311744554C526171541 @default.
• W4311744554 hasConceptScore W4311744554C62231903 @default.
• W4311744554 hasConceptScore W4311744554C71924100 @default.
• W4311744554 hasConceptScore W4311744554C97320921 @default.
• W4311744554 hasConceptScore W4311744554C98274493 @default.
• W4311744554 hasIssue "Supplement_2" @default.
• W4311744554 hasLocation W43117445541 @default.
• W4311744554 hasOpenAccess W4311744554 @default.
• W4311744554 hasPrimaryLocation W43117445541 @default.
• W4311744554 hasRelatedWork W2012186887 @default.
• W4311744554 hasRelatedWork W2050275393 @default.
• W4311744554 hasRelatedWork W2093256025 @default.
• W4311744554 hasRelatedWork W2157262647 @default.
• W4311744554 hasRelatedWork W2883678106 @default.
• W4311744554 hasRelatedWork W3001686135 @default.
• W4311744554 hasRelatedWork W3038316352 @default.
• W4311744554 hasRelatedWork W3043458966 @default.
• W4311744554 hasRelatedWork W3080423469 @default.
• W4311744554 hasRelatedWork W4311744554 @default.
• W4311744554 hasVolume "9" @default.
• W4311744554 isParatext "false" @default.
• W4311744554 isRetracted "false" @default.
• W4311744554 workType "article" @default.